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Editorial E xtraordinary leadership is required of today's hospital pharmacy director. The director of pharmacy is responsible for using fiscal and human resources to provide pharmaceutical care and guide the staff's professional development. But how does one learn and maintain salient leadership skills and develop these skills in others? How are successful pharmacists handling challenges? How can a director create a departmental philosophy that strategically leverages the role of the department within the organization? How are other directors meeting the challenge of an increasingly complex environment both clinically and technologically?
Hospital Pharmacy is pleased to announce a new monthly feature designed to help answer these questions and guide pharmacy leaders in establishing patient-centered services in small, medium, and large facilities. It is entitled Director's Forum. The first installment is included in this issue and is titled With more than 20 years of experience, Mr. Weber's research focuses on adverse drug events, medication errors, and hospital pharmacy management. He has authored more than 25 peerreviewed articles and 40 scientific abstracts on reducing medication errors, patient safety, and hospital pharmacy practice.
Mr. Weber's clinical practice has focused in the areas of critical care and internal medicine, with a specific interest in cardiovascular drug therapy, hemodynamics, and the treatment of shock states. He also focuses on the administrative aspects of clinical and hospital practice, with an emphasis on practice development; strategic planning; student, staff, and faculty coaching; drug use, disease management, and adverse drug event prevention programs; and pharmacy information systems and automation technology.
Michael Sanborn, RPh, MS, FASHP currently serves as Health System Pharmacy Director for the Baylor Healthcare System in Dallas, Texas. His responsibilities include coordination and management of pharmacy operations and clinical services at 12 hospitals with over 3,000 beds. Accomplishments include the implementation of the first system-wide Pharmacy and Therapeutics Committee, drug utilization analysis tool, therapeutic interchange program, and automation standardization.
Prior to his current position, Mr. Sanborn was the Vice President of Implementation Services for McKesson Medication Management.
Before joining McKesson, he was System Director of Pharmacy and Central Sup-ply for the NCH Healthcare System in Naples, Florida. His previous experience also includes clinical pharmacy leadership positions at The University of Kansas Medical Center and Parkland Hospital in Dallas.
Mr. Sanborn is active in a variety of pharmacy and health care organizations and has served on the Council of Administrative Affairs and the Council on Professional Affairs for ASHP; he also held elected offices for several state and local societies. He has been published more than 20 times in pharmacy practice literature on a variety of topics including: novel drug therapies, pharmacy automation, clinical pharmacy practice, quality improvement, and parenteral nutrition. He has also made over 50 presentations at various state, regional, and national pharmacy meetings. Mr. Sanborn received his BS in Hospital Pharmacy and his Masters in Hospital Pharmacy from the University of Kansas. He also completed a residency in Pharmacy Practice Management at the University of Kansas Medical Center.
This new column will be editorial in nature but will provide direction and guidance for further research. If you have specific topics that you would like us to consider publishing, please E-mail me at dcada@drugfacts.com. As the authors state in this first feature, these articles will build on one another and will serve as a "tool kit" to develop a patient-centered pharmacy service within all hospital sizes. ■
Editorial Erratum
The article entitled "Standardized Vasoactive Medications: A Unified System" appeared in the November 2005 issue. On p. 987, in Figure 1 , the standard preparations for both lidocaine and milrinone were transposed. The correct preparation should be:
Drug Weight Range (kg) Standard Preparation
Lidocaine 0 to 1.5 25 mg/50 mL D5W > 1.5 2 g/500 mL D5W Milrinone 0 to 3 2.5 mg/50 mL D5W > 3 20 mg/100 mL D5W
The editors apologize for this error. Readers are encouraged to contact the authors for future information on this article: Kristin Niemi (niemik@sutterhealth.org), Siobhan Geary (gearys@sutterhealth.org), Mark Larrabee (larrabm@sutterhealth.org), and Kevin Brown (brownk@sutterhealth.org).
